Glenmark launches Tavulus for the treatment of COPD in Spain

Glenmark Pharmaceuticals announced on Monday the launch of a bioequivalent version of the tiotropium bromide (DPI) dry powder inhaler under the brand name Tavulus in Spain.

The inhaler is used for the treatment of chronic obstructive pulmonary disease (COPD). COPD is a long-term disease that causes inflammation of the lungs, damages lung tissue, and narrows the airways, making it difficult to breathe. Studies show that almost 2.5 million people suffer from COPD in Spain.

Tavulus is expected to bring relief to a large patient population nationwide. It is a long-acting bronchodilator that helps open the airways and makes it easier to get air in and out of the lungs. It also works to prevent sudden, short-term worsening of symptoms of COPD.

According to IQVIA data, Tiotropium DPI had a market size of $ 433 million in the EU during the 12-month period ended March 2021. Tavulus is Glenmark’s bioequivalent version of Boehringer Ingelheim’s Spiriva Handihaler .

Commenting on the launch, Glenmark Pharma Vice President of Business Development, Dr JiřHavrek said: The goal of treating COPD has always been to provide rapid symptom relief to patients and reduce the risk of exacerbations. Since its launch, we have seen the multiple therapeutic benefits of Tavulus in other markets, and we are happy to extend these benefits to patients in Spain. This inhalation therapy has been shown to significantly aid in the day-to-day management of COPD. We hope it improves both COPD symptoms and the quality of life for those most affected.

In November 2017, a European subsidiary of Glenmark entered into an exclusive strategic licensing agreement for the commercialization of generic tiotropium bromide DPI in Western Europe and the United Kingdom. Glenmark anticipates further product launches in these markets under the Tiogiva brand in the UK, Ireland, Sweden, Finland and Norway; Tavulus in Denmark and the Netherlands; and Tiotropium Glenmark in Germany.

Glenmark Pharmaceuticals is a global, research-driven pharmaceutical company active in generics, specialties and over-the-counter (OTC) products and operates in more than 50 countries.

The pharmaceutical company posted a 20.7% increase in consolidated net profit to Rs 306.53 crore on a 27.6% increase in net sales to Rs 2,946 crore in the first quarter of fiscal 22 compared to first quarter of fiscal year 21.

Shares of Glenmark Pharmaceuticals closed up 1.85% at Rs 526.80 on Friday.

Powered by Capital Market – Live News

(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear reader,

Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting edge commentary on relevant current issues.
However, we have a demand.

As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital editor

About Gregory Lewis

Check Also

Saratoga Economic Development Corp. not subject to state oversight, judge rules – The Daily Gazette

ALBANY – The Saratoga Economic Development Corp. won a historic victory in its longstanding assertion …

Leave a Reply

Your email address will not be published.